Objective: To delve into the clinical efficacy of triple antiplatelet therapy (TAT) with tirofiban in treatment of elderly patients with acute coronary syndrome (ACS). Methods: From April 2015 to March 2017, a total of 100 elderly patients with ACS treated in our hospital were recruited in this study. They were randomly subdivided into the experiment group and the control group. The patients in the control group received duel antiplatelet therapy (DAT) with aspirin plus clopidogrel, while those

more »

... in the experiment group were given TAT containing tirofiban, aspirin and clopidogrel. The clinical efficacy, platelet counts, coagulation function, platelet function, the rates of major adverse cardiac events (MACE) and the incidence of adverse reactions were compared between the two groups. Results: The patients in the experiment group had a greater improvement in the clinical efficiency after TAT compared with those in the control group (P=0.031). No significant differences were observed in platelet counts and coagulation function between the two groups (Both P>0.05), but the TXB2, GMP-140 and P-selectin levels (markers for platelet function measurements) were remarkably lower in the experiment group (P=0.029, 0.036, 0.032, respectively). The differences in the rates of MACE between the two groups were significant at 24 h and 30 days (4% vs 18%, 12% vs 28%, P=0.020; 12% vs 28%, P=0.046); but the incidence of adverse reactions differed mildly (P>0.05). Conclusion: TAT of tirofiban-aspirin-clopidogrel was effective in the treatment of elderly patients with ACS, and the combination therapy was associated with more potent antiplatelet function, a lower rate of MACE and milder adverse reactions.